New York Life Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

New York Life Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,979	Closed	-$374K	–	1269
2024 Q1	$374K	Buy	10,979 +1,374	+14%	+$40.9K	﹤0.01%	897
2023 Q4	$278K	Sell	9,605 -222	-2%	-$5.89K	﹤0.01%	1244
2023 Q3	$271K	Sell	9,827 -1,548	-14%	-$47.1K	﹤0.01%	1217
2023 Q2	$342K	Sell	11,375 -1,704	-13%	-$59.6K	﹤0.01%	1181
2023 Q1	$474K	Sell	13,079 -4,472	-25%	-$172K	0.01%	1023
2022 Q4	$626K	Buy	17,551 +1,882	+12%	+$65.4K	0.01%	743
2022 Q3	$530K	Buy	15,669 +1,240	+9%	+$40.4K	0.01%	708
2022 Q2	$417K	Buy	+14,429	New	+$413K	﹤0.01%	908

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

New York Life Investment Management's SUPN Position: Q2 2024 in Review

New York Life Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2024, closing a stake of 10,979 shares — an estimated $374K sold.

New York Life Investment Management first reported a position in SUPN in Q2 2022 and held it in 8 quarters. The position peaked at $626K in Q4 2022. 245 funds tracked by Wall St. Rank hold SUPN as of Q2 2024.

New York Life Investment Management reported no remaining Supernus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
New York Life Investment Management sold 10,979 Supernus Pharmaceuticals shares in Q2 2024, an estimated $374K.
New York Life Investment Management first reported a position in Supernus Pharmaceuticals in Q2 2022 and held it in 8 quarters.
New York Life Investment Management's Supernus Pharmaceuticals position peaked at $626K in Q4 2022.
245 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.